BusinessMyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy PatientsBy Nasdaq OMXApr 2, 2018, 12:31 PM UTC
BusinessMyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy PatientsBy Nasdaq OMXMar 8, 2018, 9:02 PM UTC
